HC Wainwright Expects Lower Earnings for Pacira BioSciences

Key Points

• HC Wainwright lowered its Q2 2026 EPS estimate for Pacira BioSciences to $0.27 from $0.32, signaling weaker expected near-term earnings.
• Pacira’s latest quarterly results were mixed: it earned $0.60 per share, slightly missing estimates, while revenue of $177.38 million topped expectations and rose 5% year over year.
• Analyst sentiment remains cautious, with MarketBeat showing a consensus Hold rating and an average price target of $29.40, even as some firms raised or cut their targets after earnings.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of Pacira BioSciences in a research report issued to clients and investors on Friday, May 1st. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $0.27 per share for the quarter, down from their prior forecast of $0.32. The consensus estimate for Pacira BioSciences' current full-year earnings is $1.85 per share.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The company had revenue of $177.38 million during the quarter, compared to the consensus estimate of $171.80 million. During the same period in the prior year, the firm earned $0.65 earnings per share. The business's revenue for the quarter was up 5.0% compared to the same quarter last year.

A number of other analysts have also recently commented on PCRX. Wall Street Zen cut Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 28th. Zacks Research raised Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 7th. Barclays dropped their price target on Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 26th. Needham & Company LLC boosted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, May 1st. Finally, Royal Bank Of Canada boosted their price target on Pacira BioSciences from $22.00 to $24.00 and gave the stock a "sector perform" rating in a research report on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $29.40.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $23.15 on Monday. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. The business's 50 day moving average price is $23.36 and its 200-day moving average price is $23.17. Pacira BioSciences has a 52 week low of $18.80 and a 52 week high of $27.64. The stock has a market cap of $910.95 million, a P/E ratio of 192.93 and a beta of 0.32.

Hedge Funds Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PCRX. Doma Perpetual Capital Management LLC lifted its position in Pacira BioSciences by 49.7% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company's stock valued at $69,613,000 after acquiring an additional 897,255 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in Pacira BioSciences by 36.1% in the 2nd quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company's stock valued at $50,925,000 after acquiring an additional 565,288 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Pacira BioSciences by 49.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock valued at $27,454,000 after buying an additional 367,869 shares during the period. Hillsdale Investment Management Inc. purchased a new position in shares of Pacira BioSciences in the 4th quarter worth $7,976,000. Finally, LSV Asset Management boosted its stake in shares of Pacira BioSciences by 179.8% in the 4th quarter. LSV Asset Management now owns 319,800 shares of the company's stock worth $8,276,000 after buying an additional 205,500 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Insider Activity at Pacira BioSciences

In related news, insider Jonathan Slonin sold 3,261 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the transaction, the insider directly owned 223,640 shares of the company's stock, valued at approximately $5,103,464.80. This represents a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Shawn Cross sold 12,941 shares of the company's stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total value of $325,595.56. Following the completion of the transaction, the chief financial officer directly owned 105,341 shares in the company, valued at $2,650,379.56. This trade represents a 10.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,261 shares of company stock worth $702,610 over the last ninety days. 6.40% of the stock is currently owned by insiders.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.